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The Challenge
Developing countries carry a dispropor-
tionate share of the global disease burden
[1]. One main obstacle to developing
better tools for disease prevention—such
as vaccines against malaria, tuberculosis,
and HIV—is our limited understanding of
the underlying mechanisms of disease and
protective immunity. Genome-wide asso-
ciation (GWA) studies provide a powerful
way of getting at this problem by identi-
fying genetic variants determining resis-
tance or susceptibility to common diseases
[2–4]. GWA studies to date have mostly
focused on populations of rich countries,
and there is a case for greater scientific
investment in GWA studies relevant to the
needs of developing countries.
GWA studies in developing countries
raise a range of ethical issues. One aspect
is the need to protect the rights of the
individuals and communities who are the
subjects of the research, e.g., by develop-
ing appropriate processes for valid consent
[5]. Another aspect is to ensure that
researchers and institutions in developing
countries, who generate samples and data
for GWA studies, are not put at a scientific
disadvantage when they participate in the
large collaborative networks that are
needed to undertake this type of research
[6]. We do not attempt to deal with here
the full spectrum of ethical issues raised by
GWA studies in developing countries, but
focus specifically on the problem of
releasing data to the broader scientific
community.
There are strong scientific arguments
for data release, as the full scientific value
of a GWA study may not be realised unless
it is analysed by different methods and
combined with other datasets. For exam-
ple, meta-analyses of GWA studies in
different study populations have yielded
many important discoveries not immedi-
ately apparent from individual studies.
Several consortia undertaking large-scale
GWA studies, such as the Wellcome Trust
Case Control Consortium and the Genetic
Association Information Network, have
therefore adopted policies for releasing
anonymised GWA data with appropriate
regulatory procedures [4,7]. The question
we address here is how to develop policies
and procedures for data release appropri-
ate for GWA studies in developing coun-
tries.
Discussion about the role of data
sharing in science is not new [8,9]. Within
the context of genomics, open access
models of data release, which have their
origins in the Bermuda Principles and the
Fort Lauderdale agreement, have become
common, and most large funding bodies
now require the depositing of data in a
centralised repository [10–12]. These
moves reflect a belief that open access
promotes the scientific use and social value
of data.
While arguments for open access em-
phasise the ethical importance of promot-
ing the availability of the results of
genomic research to the scientific commu-
nity and its potential to generate important
public benefits [13–15], moves towards
open access have also generated a signif-
icant literature concerning the compatibil-
ity of open access in genomic research
with important ethical principles and
values [15]. The range of ethical issues
identified is extensive. It includes concerns
about: privacy [16,17], whether anonym-
ity can be guaranteed [15,17–19], security
[17], the implications of collecting and
storing vast amounts of data and about its
uncertain future use [17], the implications
of data release for populations [16,18,20]
and for family members of participants
[16,17], the need to strike a proper
balance between research and protection
[15], the development of appropriate
governance mechanisms [14,15], the im-
plications for trust, consent, and autonomy
[16,19,21,22], commercialisation [23],
and the ethical importance of the sustain-
ability of databases [24].
Despite this theoretical literature, there
are no empirically grounded accounts of
the ethical challenges in the development
of data release policies in GWA studies in
developing countries. Here we describe
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policy for the Malaria Genomic Epidemi-
ology Network (MalariaGEN), a partner-
ship of malaria researchers in over 20
countries supported by the Grand Chal-
lenges in Global Health initiative [25].
MalariaGEN investigators are using a
range of genetic epidemiological ap-
proaches to investigate mechanisms of
protective immunity against malaria, as
part of the global effort to develop an
effective malaria vaccine. MalariaGEN
has sought to establish fair rules for
sharing samples and data in large-scale
research collaborations, a key principle
being that contributing investigators retain
ownership of the samples that they con-
tribute to consortial projects [25]. Thus
the datasets generated by individual inves-
tigators are not governed by the data-
release policy described here, apart from
specific items of phenotypic information
that have been contributed by the inves-
tigators to consortial projects for the
purpose of GWA analysis.
Developing Policies and
Mechanisms to Govern Release
of GWA Data
Although MalariaGEN was founded
with open access in mind [6], it was clear
that the development of an effective,
appropriate approach to GWA data re-
lease required widespread consultation
across the network and with external
stakeholders (see Figure 1). In what
follows, we outline some of the key issues
arising during this process and how these
were addressed.
From Open Access to Managed
Open Access
The Fort Lauderdale agreement calls
for the immediate release of genomic data
to the scientific community, constrained
only by the need to protect the rights of
data producers to pursue their stated
scientific aims without being ‘‘scooped’’
by those who gain access to their data
[26]. Although MalariaGEN investigators
supported this general principle, after
extensive discussion and consultation it
was concluded that it would be inappro-
priate to provide entirely open public
access to GWA data on individuals
accompanied by specific phenotypic data.
One factor in this decision was the
scientific importance of information about
an individual’s ethnic group. Many com-
munities in Africa have considerable
complexity in population structure, i.e.,
they are composed of several ethnic
groups that differ in their frequency of
common genetic variants, so that knowl-
edge about an individual’s ethnic group is
needed by researchers to determine
whether an apparent genetic association
is truly related to disease susceptibility or is
an artefact caused by these ethnic differ-
ences. In theory, samples from different
ethnic groups or geographic regions might
be distinguished without naming them
explicitly, e.g., by labelling them 001,
002, etc., but a relatively simple statistical
calculation would break such a code.
Following consultation, it was therefore
agreed that access to MalariaGEN data-
sets would be mediated via an indepen-
dent data-access committee (IDAC) (see
Figure 2), and that researchers would be
granted access to genotyping data and to a
limited amount of clinical and demo-
graphic data only after signing a legally
binding data-access agreement (see http://
www.malariagen.net/resource/2).
MalariaGEN took some time to reach a
consensus about the IDAC’s composition,
role, and remit. Questions arising during
the process included how best to strike an
appropriate balance between the indepen-
dence of the DAC and ensuring sufficient
expertise to review applications, and how
to ensure resources for its long-term
sustainability. Stakeholders consulted dur-
ing development of the policy emphasised
that the IDAC would need to be able to
take into account the interests of research
participants, communities, ethics commit-
tees, and MalariaGEN Principal Investi-
gators from developing countries. In the
context of a collaborative network involv-
ing research groups in many countries, it
was not feasible to have representatives for
each sample set on the IDAC. Given this,
the decision was made to appoint a small
number of members (six in the first
instance) each with multiple relevant areas
of expertise, to facilitate timely and
rigorous review. To complement the
IDAC, it is proposed to establish a broader
consultative group involving partner insti-
tutions, ethical review bodies, and funding
agencies that will receive regular reports of
the uses made of the released data and
may be asked to consider issues of policy
from time to time by IDAC. This
mechanism will enable widespread en-
gagement with the process of data release,
without requiring members to undertake
case-by-case consideration of all data
access applications.
Acceptable Uses of Data
A further issue arising in consultation
concerned the restrictions to be placed
upon the kinds of research allowable using
data. For example, should the use of data
be restricted to ‘‘medical research’’ or
should anthropological research be per-
mitted? Clearly, the ethical release and use
of data requires respect to be paid to the
conditions under which the original con-
sent was obtained. While there is currently
a lively international debate about appro-
priate models of consent for GWA studies
[5,17,27], many MalariaGEN samples
were collected at a time when current
Figure 1. MalariaGEN’s process for developing a GWA data-release policy.
doi:10.1371/journal.pmed.1000143.g001
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sharing were unenvisaged. The potential
uses and benefits of data often extend far
beyond the original purpose specified in
the consent form. There are arguments in
favour of the use of such data, given
appropriate safeguards and where the use
might reasonably be considered to be
something to which the donor would have
consented. But, if it is not realistic to go
back to participants to obtain their con-
sent, how should decisions about appro-
priate access and research use be made?
The IDAC came to the view that the
need to interpret the scope of the original
ethics approval and consent meant that
determining acceptable forms of research
on data would require input from relevant
research ethics committees. At present
IDAC engages with local ethics commit-
tees for specific sample sets as they become
due for release, to determine exactly how
broad a range of research purposes is
considered acceptable. In some cases
ethics committees may reserve the right
to consider applications for access for what
they consider to be borderline research
purposes on a case-by-case basis (see
http://www.malariagen.net/resource/2).
Timing
The Fort Lauderdale agreement em-
phasises that the scientific work and
aspirations of data producers should be
recognised and not undermined by open
access. In the context of genomic data
produced by researchers in developing
countries, there is a possibility that were
such data released immediately to the
wider scientific community, these re-
searchers would be ‘‘scooped’’ by those
from richer countries. This suggests a level
of protection might be appropriate.
The primary purpose of open access is
the promotion of appropriate research.
MalariaGEN takes the view that capacity-
building in developing country research is
important both to the future success of
addressing the health care needs of
developing countries through the develop-
ment of local expertise, and to promoting
the trust underpinning the viability of
multinational scientific networks upon
which such success to a large degree
depends. The Network came to the view
that its data-sharing policy must, in
addition to promoting science in the short
term, promote science and the conditions
necessary for science relevant to develop-
ing countries in the longer term.
For these reasons, the policy allows for a
delay in data release for up to nine months
after MalariaGEN investigators at the
study site have access to their dataset.
This, combined with other capacity-build-
ing measures, should assist in balancing
the significant differences in analytic
capacity present in developed and devel-
oping countries. Where principal investi-
gators from the study site agree, data may
nevertheless be released immediately
along with notification of areas of research
the MalariaGEN Network and individual
principal investigators are undertaking
with the dataset (see, for example http://
www.malariagen.net/resource/2). Appli-
cants accessing the data are asked to
respect these areas of research and refrain
from publishing analyses in them prior to
the initial MalariaGEN publications on
those topics.
Looking Forward
The purpose of the MalariaGEN data-
release policy is to promote the scientific
use and the social value of its data. There
is a need to find effective mechanisms to
communicate the key findings of the
research, and how the released data have
been used by the scientific community, to
participating communities and to local
research ethics committees. There is also
a need to find effective and appropriate
ways of conveying the purpose of the
research and exploring its social and
cultural implications if local communities
are to be able to participate effectively in
debates about the release of GWA data.
This need is of particular importance in
relation to data on ethnicity, and how
individual ethnic groups are to be iden-
tified and labelled. Genetic researchers
need to work with social scientists and
with research ethics committees to un-
derstand how such issues are perceived by
local communities, and to ensure that
t h e s ev i e w sa r er e s p e c t e di nt h er e l e a s e d
data.
It is our view that an ethical data-release
policy must, in addition to providing
adequate protections for research partici-
pants and their communities, be combined
with adequate protections for the research
aspirations of developing country scientists
and with capacity-building activities to
ensure that those aspirations have the
potential to be realised. Collaborative
global health research capable of address-
ing the needs of people in developing
countries depends crucially upon the
building of capacity in developing country
sites to enable locally held clinical and
phenotypic data to be analysed locally in
combination with genotype data. This has
the potential to lead to the identification of
key site-specific factors that play a role in
the development of malaria. What this
means is that the sharing of genotypic and
phenotypic data is by itself insufficient
without the sharing of expertise. For this
reason MalariaGEN is complementing its
data-release policy with a programme for
the training and support of data-fellows in
malaria-endemic partner sites to strength-
en capacity for genetic data analysis across
Figure 2. Data application process.
doi:10.1371/journal.pmed.1000143.g002
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within the team of a MalariaGEN inves-
tigator and have responsibilities for man-
aging the team’s data. Senior data-fellows
help to provide mentorship for the group
(http://www.malariagen.net/resource/2).
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